Mawu Oyamba
Tirzepatide, yopangidwa ndi Eli Lilly, ndi mankhwala atsopano a peptide omwe amayimira gawo lalikulu pakuchiza matenda amtundu wa 2 komanso kunenepa kwambiri. Mosiyana ndi ma agonist achikhalidwe a GLP-1 (glucagon-ngati peptide-1), Tirzepatide imagwira ntchito.GIP (yodalira glucose-insulinotropic polypeptide)ndiGLP-1 receptors, kupeza dzina la aawiri receptor agonist. Njira yapawiriyi imathandizira kuyendetsa bwino shuga m'magazi ndikuchepetsa kulemera kwa thupi, makamaka kwa odwala omwe ali ndi matenda amtundu wa 2 komanso kunenepa kwambiri.
Njira Yochitira
-
GIP receptor activation: Imawonjezera katulutsidwe ka insulini ndikuwongolera kulolerana kwa glucose.
-
GLP-1 receptor activation: Imathandizira kutulutsidwa kwa insulin, imachepetsa katulutsidwe ka glucagon, komanso imachepetsa kutulutsa m'mimba.
-
Pawiri synergy: Imawongolera bwino glycemic ndikuchepetsa kwambiri kulemera.
Clinical Data Analysis
1. Mayesero a SURPASS (Mtundu Wachiwiri wa Shuga)
Pafupi ndi zambiriSURPASS mayesero azachipatala, Tirzepatide inaposa insulini ndi Semaglutide mu zotsatira za glycemic ndi kuchepetsa kulemera.
| Gulu la Odwala | Mlingo | Avg. Kuchepetsa HbA1c | Avg. Kuonda |
|---|---|---|---|
| Type 2 shuga mellitus | 5 mg pa | -2.0% | -7.0 kg |
| Type 2 shuga mellitus | 10 mg pa | -2.2% | -9.5 kg |
| Type 2 shuga mellitus | 15 mg pa | -2.4% | - 11.0 kg |
➡ Poyerekeza ndi Semaglutide (1 mg: HbA1c -1.9%, Kulemera -6.0 kg), Tirzepatide inasonyeza zotsatira zapamwamba pa zonse za glycemic control ndi kulemera kwa thupi.
2. SURMOUNT mayesero (Kunenepa)
Odwala onenepa kwambiri omwe alibe matenda a shuga, Tirzepatide adawonetsa kuchita bwino kwambiri pakuchepetsa thupi.
| Mlingo | Avg. Kuchepetsa Kunenepa (masabata 72) |
|---|---|
| 5 mg pa | -15% |
| 10 mg pa | -20% |
| 15 mg pa | -22.5% |
➡ Kwa wodwala wolemera makilogalamu 100, mlingo waukulu wa Tirzepatide ukhoza kuchepetsa kulemera kwa kuzungulira.22.5 kg.
Ubwino waukulu
-
Njira ziwiri: Kupitilira ma agonist amodzi a GLP-1.
-
Kuchita bwino kwambiri: Kuchita bwino pakuwongolera glycemic komanso kuwongolera kulemera.
-
Lonse kugwiritsa ntchito: Ndioyenera pa matenda a shuga komanso kunenepa kwambiri.
-
Kuthekera kwakukulu kwa msika: Kuwonjezeka kwa kufunikira kwa kunenepa kwambiri kwa Tirzepatide ngati mankhwala amtsogolo a blockbuster.
Market Outlook
-
Zoneneratu za kukula kwa msika: Pofika 2030, msika wapadziko lonse wa mankhwala a GLP-1 ukuyembekezeka kupitilira$ 150 biliyoni, ndi Tirzepatide mwina kutenga gawo lalikulu.
-
Malo opikisana: Mdani wamkulu ndi Novo Nordisk's Semaglutide (Ozempic, Wegovy).
-
Ubwino: Deta yachipatala imasonyeza Tirzepatide imapereka kulemera kwakukulu poyerekeza ndi Semaglutide, kulimbitsa mpikisano wake wamsika mu chithandizo cha kunenepa kwambiri.
Nthawi yotumiza: Sep-12-2025